Project title: Dual specificity phosphatase 6 is a novel therapeutic target in neuroendocrine tumors

Description

What critical problem/question will researchers try to answer?
For patients with neuroendocrine tumors (NETs), treatment challenges remain significant. NET cancers lack effective and novel therapeutic targets, making it difficult to develop breakthrough therapies. Additionally, complete responses to treatment are rare, and resistance to therapy—whether present from the start (primary resistance) or developing over time (acquired resistance)—occurs frequently.

Why is this important?
This is important because the lack of effective and novel therapeutic targets, combined with the rarity of complete treatment responses and frequent resistance to therapy, severely limits the options for managing NETs. As a result, many patients face a prolonged disease course with suboptimal outcomes. Addressing these challenges through the discovery of new therapeutic targets and strategies is critical for improving survival rates, reducing tumor progression, and enhancing the quality of life for NET patients.

What will the researchers do?
We aim to explore the role of dual specificity phosphatase 6 (DUSP6) in NETs. DUSP6 is an enzyme that plays a key role in cancer growth and progression and is a promising target for overcoming resistance to treatments like chemotherapy. This project has two main goals: (1) to understand how DUSP6 drives NET development and (2) to investigate whether blocking DUSP6 can improve treatment success. By combining advanced methods, laboratory models, and patient samples, this study seeks to develop personalized, more effective therapies for better outcomes.

How might this improve treatment of neuroendocrine cancer?
This research could lead to better treatments for NETs by focusing on DUSP6, a key driver of tumor growth and treatment resistance. Blocking DUSP6 might make existing therapies, like chemotherapy, work more effectively. It could also help doctors tailor treatments to individual patients based on specific tumor characteristics, leading to better outcomes and new options for people with limited treatment choices.

What is the next step?
Confirming DUSP6 as a treatment target could pave the way for new clinical research and drug development. Future trials could test DUSP6 inhibitors on their own or alongside other treatments, offering more options for patients. Combining DUSP6-targeted therapies with existing therapies for NETs may enhance treatment effectiveness, helping to control tumor growth and metastasis more safely. This approach could lead to longer periods without disease progression and better long-term outcomes for patients.

« Back to all funded research projects